BioDlink International Approves Major CDMO Master Services Agreement at Extraordinary General Meeting
Hong Kong, 11 June 2026 — BioDlink International Company Limited (Stock Code: 1875) has announced the results of its Extraordinary General Meeting (EGM) held on 11 June 2026, where shareholders overwhelmingly approved a significant transaction that could have substantial implications for the company’s future operations and share value.
Key Points from the EGM
- Approval of CDMO Master Services Agreement: Shareholders passed an ordinary resolution to approve, confirm, and ratify the CDMO master services agreement dated 26 May 2026 between BioDlink International and WuXi XDC Cayman Inc., including all transactions contemplated under this agreement.
- Annual Caps for 2026-2028: The EGM also approved the proposed annual caps for the contract for each of the years ending 31 December 2026, 2027, and 2028.
- Authorization for Further Actions: Directors and other authorized persons have been empowered to execute any necessary documents and arrangements, as well as approve immaterial variations or amendments in connection with the agreement, as deemed in the interests of the company and its shareholders.
- Strong Shareholder Support: The resolution received overwhelming approval, with 99.90% of votes cast in favor (140,917,540 shares), and only 0.10% against (137,600 shares).
- Voting Exclusions: WuXi XDC and its associates, holding 468,853,184 shares, were required to abstain from voting due to listing rules regarding related party transactions, ensuring compliance and fair voting procedures.
- Additional Voting Restrictions: Trustees under the company’s restricted share award scheme, holding 12,722,993 shares, did not exercise voting rights on these shares as required by the scheme and listing rules.
- Scrutineer and Attendance: Tricor Investor Services Limited acted as the scrutineer for the poll, and key directors attended the EGM via electronic means.
Important Information for Shareholders
- Material Transaction: The CDMO master services agreement represents a significant business arrangement with WuXi XDC Cayman Inc., a major player in the contract development and manufacturing organization (CDMO) sector. This could position BioDlink International for substantial growth in its service capabilities, revenue streams, and strategic partnerships over the next three years.
- Potential Price-Sensitive Information: The approval of the agreement and the clear mandate from shareholders may be viewed positively by the market, as it underscores confidence in the company’s direction and ability to form strategic alliances. Any successful execution or expansion of this agreement could have a material effect on future earnings, business scale, and, consequently, share price.
- Rigorous Compliance: The company has strictly adhered to Hong Kong’s Listing Rules regarding related party transactions and voting procedures, signaling strong corporate governance, which is often looked upon favorably by institutional investors.
- No Treasury Shares Voted: BioDlink International does not hold any treasury shares, and none were voted at the EGM.
- No Dissent Indicated: No shareholders had indicated any intention to vote against or abstain aside from those required by the rules.
Board Composition and Attendance
- Executive Director: Dr. Jincai Li (Chairperson)
- Non-Executive Director: Mr. Xiaojie Xi
- Independent Non-Executive Directors: Mr. Xin Fan, Dr. Ulf Grawunder, Dr. Chaohong Hu
- Dr. Jincai Li, Dr. Ulf Grawunder, and Dr. Chaohong Hu attended the EGM electronically.
Summary
The decisive approval of the CDMO master services agreement with WuXi XDC Cayman Inc. at the EGM is a material development for BioDlink International Company Limited. Investors should closely monitor developments related to the execution of this agreement, as it could significantly influence the company’s business trajectory and share price going forward.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should seek professional advice before making any investment decisions. The author and publisher are not responsible for any losses arising from reliance on the information provided above.
BioDlink國際於特別股東大會批准重磅CDMO主服務協議
香港，2026年6月11日 — BioDlink International Company Limited（股份代號：1875）公佈於2026年6月11日舉行的特別股東大會（EGM）投票結果，股東壓倒性通過一項重大交易，對公司未來營運及股價或有重大影響。
特別股東大會重點
- 批准CDMO主服務協議： 股東通過普通決議，批准、確認並認可BioDlink國際與WuXi XDC Cayman Inc.於2026年5月26日簽訂的CDMO主服務協議及其相關交易。
- 2026-2028年度上限： 會議同時通過協議於2026、2027及2028年度的年度交易上限。
- 授權董事進一步行動： 董事及獲授權人士可簽署所有必要文件，及針對協議作出不重大變動或修訂，以保障公司及全體股東利益。
- 股東高度支持： 決議獲得壓倒性支持，99.90%投票贊成（140,917,540股），僅0.10%反對（137,600股）。
- 投票權限制： WuXi XDC及其關聯方（共持有468,853,184股）根據上市規則需避席投票，確保投票公正合規。
- 股份獎勵計劃限制： 公司股份獎勵計劃的受託人（共持有12,722,993股）根據相關規則未有行使投票權。
- 監票及參與： Tricor Investor Services Limited為是次投票監票人，主要董事以電子方式參與會議。
股東須知及潛在影響
- 重大業務協議： CDMO主服務協議屬與行業巨頭WuXi XDC Cayman Inc.的重要合作，有望大幅提升BioDlink國際未來三年的服務能力、收入及戰略合作空間。
- 或具價格敏感信息： 協議獲股東明確授權，反映市場對公司發展方向及戰略夥伴信心。協議執行或擴展均有潛力對未來盈利、業務規模及股價產生重大正面影響。
- 嚴格合規： 公司嚴格遵守香港上市規則對關連交易及投票的規定，體現良好企業管治，對機構投資者屬正面訊號。
- 無庫存股投票： BioDlink國際並無持有或投票任何庫存股。
- 無其他股東異議： 除規定需避席者外，無任何股東表示反對或棄權。
董事會組成及出席
- 執行董事：李金才博士（主席）
- 非執行董事：奚曉捷先生
- 獨立非執行董事：范鑫先生、Dr. Ulf Grawunder、胡朝紅博士
- 李金才博士、Dr. Ulf Grawunder及胡朝紅博士以電子方式出席會議。
總結
是次與WuXi XDC Cayman Inc.的CDMO主服務協議獲得通過，對BioDlink國際而言屬具體而重大的發展。投資者宜密切留意協議落實及後續進展，因相關執行可能顯著左右公司業績及股價走勢。
免責聲明： 本文僅供參考，並不構成任何投資建議。投資者應尋求專業意見，作者及出版方對因依賴上述資料而造成的損失概不負責。
